Skip to content
Research/Gene Therapy/AAV9-Follistatin Gene Therapy

AAV9-Follistatin Gene Therapy

AAV9-Follistatin gene therapy involves using an adeno-associated virus (AAV9) vector to deliver the follistatin gene into cells. Follistatin is a protein that inhibits myostatin, a growth factor that limits muscle growth. This therapy aims to enhance muscle mass and strength, which could be beneficial for age-related muscle loss and other muscle-wasting conditions, contributing to improved longevity and healthspan.

Intelligence Profile

Clinical Applications

Currently, there is limited specific evidence on AAV9-Follistatin Gene Therapy applications from the provided references. However, there is a clinical trial (NCT ID: NCT07443826) indicating that this therapy is being investigated for its potential to counteract age-related muscle loss. This study is in the recruitment phase and combines AAV-Follistatin with an angiogenesis-inducing VEGF plasmid gene therapy to explore its effects on muscle preservation and regeneration.

The evidence provided lacks direct findings specific to AAV9-Follistatin, suggesting that ongoing and future research is required to better understand its clinical applications and effectiveness.

Disclaimer: This is a general overview and should not be taken as medical advice. Always consult healthcare professionals for specific medical recommendations.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.